Jin Medical International (ZJYL)
Customizable rehabilitation wheelchairs and living aids for dealer markets.
$2.14
Pre-market−0.01 (−0.54%)
At close$2.15(−2.27%)
In millions of USD, except per-share figures
| In millions | Q4 FY20Sep 2020 | Q2 FY21Mar 2021 | Q4 FY21Sep 2021 | Q2 FY22Mar 2022 | Q4 FY22Sep 2022 | Q2 FY23Mar 2023 | Q4 FY23Sep 2023 | Q2 FY24Mar 2024 | Q4 FY24Sep 2024 | Q2 FY25Mar 2025 | Q4 FY25Sep 2025 | Q2 FY26Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 9 | 11 | 9 | 10 | 10 | 10 | 11 | 13 | 10 | 11 | 9 |
| Cost of revenue | 6 | 6 | 8 | 6 | 7 | 7 | 6 | 7 | 7 | 7 | 7 | 7 |
| Gross profit | 3 | 4 | 3 | 3 | 3 | 4 | 3 | 4 | 6 | 3 | 4 | 2 |
| 2 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | |
| Research & development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| General & administrative | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 0 | 0 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 0 | 1 | −1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 0 | 2 | 0 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 0 | 1 | 0 |
| Net income | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 0 | 1 | 0 |
| EPS, basic | $0.05 | $0.09 | $0.04 | $0.18 | $0.22 | $0.26 | $0.14 | $0.23 | $0.24 | −$0.01 | $0.16 | −$0.01 |
| EPS, diluted | $0.05 | $0.09 | $0.04 | $0.18 | $0.22 | $0.26 | $0.14 | $0.23 | $0.24 | −$0.01 | $0.16 | −$0.01 |
| Weighted average shares, basic | 20 | 20 | 20 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 8 |
| Weighted average shares, diluted | 20 | 20 | 20 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 8 |
| EBITDA | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 0 | 1 | 0 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 0 | 1 | −1 |